All Posts

FYI: We made some adjustments to our Run-Up portfolio holdings today based on recent past readouts and a near-term upcoming readout. We closed our positions in CELC (5.6% to 0%) and CMPS (5.6% to 0%) and cut our position in TENX in half to 2.8% to reduce exposure with the upcoming Ph3 (suspected big mover) readout this month. Next major adjustments to the Run-Up targets likely not until after the Q2 hedge fund data is available in mid-August. We provide our holdings and perce

Q2 earnings reports are arriving quickly, with several notable Bio/Pharma companies scheduled to report between August 5 and August 12. For this earnings watchlist, BPIQ evaluated its model-portfolio positions, tracked hedge-fund participation, financial indicators, commercial performance and upcoming clinical and regulatory catalysts. The strongest concentration of signals is found in CYTK, RVMD, MIRM, XENE and CMPS. Five additional companies complete BPIQ’s Top 10, ad

10 Hot Bio/Pharma Stocks on BPIQ’s Q2 Earnings Radar

Explore hedge fund positions and BPIQ model-portfolio overlap in Terns, Centessa, and RAPT before their 2026 biotech M&A deals.

Three hedge fund-backed biopharma picks. One revealed. See why COGT stands out ahead of two FDA decisions, then unlock the other two July 2026 picks.

Explore BPIQ’s July 2026 biopharma hedge fund stock picks, COGT, IRON, and TENX, and the key regulatory, Phase 3, and pipeline catalysts ahead.

Explore BPIQ’s July 2026 biopharma hedge fund stock picks, $COGT, $IRON, and $TENX, and the key regulatory, Phase 3, and pipeline catalysts ahead.

The bio/pharma IPO market reopened in H1 2026, as we predicted based on the bullish public bio/pharma market starting in the 2nd half of 2025. However, the bio/pharma IPO activity remains far below its historical peak in 2020/2021. BPIQ recorded 15 IPOs in H1 2026, up 114% from seven in H1 2025. This was the highest first-half total since 2021, but only narrowly above the 14 IPOs recorded in H1 2022 and still far below the 61 recorded in H1 2021. Quarterly Activity Shows a Gr

H1 2026 private bio/pharma funding reached its highest total amount invested of the past three years, but the number of funding events declined by almost 33%. Total capital increased slightly compared with H1 2024 and H1 2025, while funding activity remained well below prior-year levels. This points to an investment environment where capital is still available, but fewer companies are securing it. In total, private companies raised approximately $20.3B across 366 funding even

BPIQ has released its H2 2026 Big Movers list, highlighting biotech catalysts with the greatest potential to drive meaningful stock moves. The list includes 18 Big Movers and 79 Suspected Movers. Suspected Movers are catalysts BPIQ identifies as having significant stock-move potential. Big Movers are near-term Suspected Movers where options-implied volatility confirms that the market is pricing in a large move. Elite and APEX subscribers can also see whether a Big Mover is de